Antitumor effects of co-treatment of resveratrol with antitumor drugs in ER- and HER2-positive breast cancer cells are due to induction of apoptosis and modulation of estrogen receptor expression.

IF 4 3区 医学 Q1 OBSTETRICS & GYNECOLOGY Breast Cancer Pub Date : 2024-09-01 Epub Date: 2024-05-23 DOI:10.1007/s12282-024-01590-6
Beatriz Tinoco Franceschi, Patrícia Heloise Alves Bezerra, Maria Regina Torqueti
{"title":"Antitumor effects of co-treatment of resveratrol with antitumor drugs in ER- and HER2-positive breast cancer cells are due to induction of apoptosis and modulation of estrogen receptor expression.","authors":"Beatriz Tinoco Franceschi, Patrícia Heloise Alves Bezerra, Maria Regina Torqueti","doi":"10.1007/s12282-024-01590-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Resveratrol, a natural compound, may be an alternative to improving conventional breast cancer therapy. Thus, we assessed the capability of resveratrol at a low dose to enhance the in vitro effect of conventional theray in estrogen receptor (ER) and human epidermal growth factor receptor type 2 (HER2)-positive breast cancer cells.</p><p><strong>Methods: </strong>Cell viability of breast cancer cells was measured with neutral red uptake assay. Apoptosis, autophagy, cell cycle progression and cell proliferation were detected through hypotonic fluorescent solution assay, formation of acidic vesicular organelles, flow cytometry, and bromodeoxyuridine assay, respectively. Western blotting was performed to study the expression of pro-apoptotic, anti-apoptotic and autophagic proteins, and estrogen receptors.</p><p><strong>Results: </strong>Resveratrol combined with tamoxifen metabolites or trastuzumab reduced cell viability of ER- and HER2-positive breast cancer cells, respectively. This effect was mainly associated with induction of apoptosis due to a greater formation of hypodiploid nuclei, reduced protein expression of procaspase-7, Bcl-2, Bcl-xL, and PARP; and increased expression of cleaved PARP. Resveratrol decreased the expression of ERα and increased that of ERβ, contributing to the reduced viability on breast cancer cells. Combined treatments induced autophagy, evidenced by increased levels of acidic vesicular organelles and degradation of p62/SQSTM1 protein. Nevertheless, on inhibiting autophagy with 3-methyladenine, cell viability was further reduced and apoptosis was induced, suggesting a pro-survival role of autophagy, impairing apoptosis.</p><p><strong>Conclusions: </strong>Resveratrol increasead the in vitro cytotoxic effect of conventional therapy in breast cancer cells. However, it was necessary to block resveratrol-induced autophagy to improve the therapeutic response.</p>","PeriodicalId":56083,"journal":{"name":"Breast Cancer","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12282-024-01590-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Resveratrol, a natural compound, may be an alternative to improving conventional breast cancer therapy. Thus, we assessed the capability of resveratrol at a low dose to enhance the in vitro effect of conventional theray in estrogen receptor (ER) and human epidermal growth factor receptor type 2 (HER2)-positive breast cancer cells.

Methods: Cell viability of breast cancer cells was measured with neutral red uptake assay. Apoptosis, autophagy, cell cycle progression and cell proliferation were detected through hypotonic fluorescent solution assay, formation of acidic vesicular organelles, flow cytometry, and bromodeoxyuridine assay, respectively. Western blotting was performed to study the expression of pro-apoptotic, anti-apoptotic and autophagic proteins, and estrogen receptors.

Results: Resveratrol combined with tamoxifen metabolites or trastuzumab reduced cell viability of ER- and HER2-positive breast cancer cells, respectively. This effect was mainly associated with induction of apoptosis due to a greater formation of hypodiploid nuclei, reduced protein expression of procaspase-7, Bcl-2, Bcl-xL, and PARP; and increased expression of cleaved PARP. Resveratrol decreased the expression of ERα and increased that of ERβ, contributing to the reduced viability on breast cancer cells. Combined treatments induced autophagy, evidenced by increased levels of acidic vesicular organelles and degradation of p62/SQSTM1 protein. Nevertheless, on inhibiting autophagy with 3-methyladenine, cell viability was further reduced and apoptosis was induced, suggesting a pro-survival role of autophagy, impairing apoptosis.

Conclusions: Resveratrol increasead the in vitro cytotoxic effect of conventional therapy in breast cancer cells. However, it was necessary to block resveratrol-induced autophagy to improve the therapeutic response.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
白藜芦醇与抗肿瘤药物联合治疗 ER- 和 HER2 阳性乳腺癌细胞的抗肿瘤作用是由于诱导细胞凋亡和调节雌激素受体的表达。
背景:白藜芦醇是一种天然化合物,它可能是改善传统乳腺癌治疗的一种替代方法。因此,我们评估了低剂量白藜芦醇增强传统疗法对雌激素受体(ER)和人类表皮生长因子受体 2 型(HER2)阳性乳腺癌细胞体外效应的能力:方法:用中性红吸收法测定乳腺癌细胞的活力。分别通过低渗荧光溶液检测法、酸性囊泡细胞器形成法、流式细胞术和溴脱氧尿苷检测法检测细胞凋亡、自噬、细胞周期进展和细胞增殖。结果显示,白藜芦醇与他莫昔芬联合用药后,雌激素受体和促凋亡蛋白、抗凋亡蛋白、自噬蛋白的表达均明显下降:结果:白藜芦醇与他莫昔芬代谢物或曲妥珠单抗联合使用,可分别降低ER阳性和HER2阳性乳腺癌细胞的存活率。这种效应主要与诱导细胞凋亡有关,因为细胞核二倍体形成增多,procaspase-7、Bcl-2、Bcl-xL 和 PARP 蛋白表达减少,以及裂解 PARP 表达增加。白藜芦醇降低了ERα的表达,增加了ERβ的表达,从而降低了乳腺癌细胞的存活率。联合治疗可诱导自噬,表现为酸性囊泡细胞器水平的增加和 p62/SQSTM1 蛋白的降解。然而,用3-甲基腺嘌呤抑制自噬后,细胞活力进一步降低,并诱导细胞凋亡,这表明自噬具有促进生存、抑制细胞凋亡的作用:结论:白藜芦醇能增强传统疗法对乳腺癌细胞的体外细胞毒性作用。结论:白藜芦醇能增强传统疗法对乳腺癌细胞的体外细胞毒性作用,但要提高治疗效果,必须阻断白藜芦醇诱导的自噬作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Breast Cancer
Breast Cancer ONCOLOGY-OBSTETRICS & GYNECOLOGY
CiteScore
6.70
自引率
2.50%
发文量
105
审稿时长
6-12 weeks
期刊介绍: Breast Cancer, the official journal of the Japanese Breast Cancer Society, publishes articles that contribute to progress in the field, in basic or translational research and also in clinical research, seeking to develop a new focus and new perspectives for all who are concerned with breast cancer. The journal welcomes all original articles describing clinical and epidemiological studies and laboratory investigations regarding breast cancer and related diseases. The journal will consider five types of articles: editorials, review articles, original articles, case reports, and rapid communications. Although editorials and review articles will principally be solicited by the editors, they can also be submitted for peer review, as in the case of original articles. The journal provides the best of up-to-date information on breast cancer, presenting readers with high-impact, original work focusing on pivotal issues.
期刊最新文献
Comparative assessment of breast volume using a smartphone device versus MRI. Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM). High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands. Comparison of locoregional recurrence risk among nipple-sparing mastectomy, skin-sparing mastectomy, and simple mastectomy in patients with ductal carcinoma in situ: a single-center study. Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1